nach oben

Erschienen in:

30.08.2019 | Preclinical study

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy

verfasst von: Lutfi H. Alfarsi, Rokaya El Ansari, Madeleine L. Craze, Michael S. Toss, Brendah Masisi, Ian O. Ellis, Emad A. Rakha, Andrew R. Green

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Endocrine therapy is the standard treatment for oestrogen receptor positive (ER+) breast cancer. Despite its efficacy, around half of patients will develop resistance to this treatment and eventually relapse. Identification of effective and reliable biomarkers to predict the efficacy of endocrine therapy is of crucial importance in the management of ER+ breast cancer. Emerging evidence has revealed that the cell division regulator CDC20 exhibits an oncogenic function and plays important roles in tumourigenesis and progression of solid tumours. In this study, we investigated the prognostic and predictive role of CDC20 in early ER+ breast cancer patients.

Methods

The biological and clinical impact of CDC20 expression was assessed in large clinical annotated cohort of ER+ breast cancer with long-term follow-up at the mRNA level, using METABRIC and KM-Plotter datasets, and the protein level using immunohistochemistry on patients presenting at Nottingham. CDC20 expression was correlated with clinico-pathological parameters, molecular subtypes, clinical outcome and efficacy of endocrine therapy.

Results

High CDC20 mRNA expression was associated with poor clinico-pathological parameters including large tumour size and high tumour grade (P < 0.0001) in patients with ER+ breast cancer. High CDC20 mRNA expression was significantly associated with poor patient outcome (P < 0.0001). Importantly, high CDC20 expression was correlated with poor response to endocrine treatment in patients who treated with hormonal therapy only (P < 0.01). In multivariate analysis, CDC20 mRNA was an independent predictor of poor clinical outcome after treatment with endocrine therapy (P = 0.02).

Conclusion

CDC20 is a candidate biomarker for a subgroup of ER+ breast cancer characterised by poor clinical outcome. This study shows that the CDC20 could act as potential predictive biomarker of poor response to endocrine therapy in ER+ breast cancer.

Nur mit Berechtigung zugänglich

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093 CrossRefPubMed

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25(30):4772–4778. https://doi.org/10.1200/jco.2007.12.2747 CrossRefPubMed

Dawson SJ, Rueda OM, Aparicio S, Caldas C (2013) A new genome-driven integrated classification of breast cancer and its implications. The EMBO J 32(5):617–628. https://doi.org/10.1038/emboj.2013.19 CrossRefPubMed

Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631–643. https://doi.org/10.1038/nrc2713 CrossRefPubMed

Group EBCTC (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0 CrossRef

Early Breast Cancer Trialists’ Collaborative G (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. https://doi.org/10.1016/S0140-6736(11)60993-8 CrossRef

Weinstein J (1997) Cell cycle-regulated expression, phosphorylation, and degradation of p55Cdc. A mammalian homolog of CDC20/Fizzy/slp1. J Biol Chem 272(45):28501–28511CrossRef

Weinstein J, Jacobsen FW, Hsu-Chen J, Wu T, Baum LG (1994) A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4. Mol Cell Biol 14(5):3350–3363CrossRef

Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S (2007) Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28(1):81–92. https://doi.org/10.1093/carcin/bgl100 CrossRefPubMed

10.

Wang Z, Wan L, Zhong J, Inuzuka H, Liu P, Sarkar FH, Wei W (2013) Cdc20: a potential novel therapeutic target for cancer treatment. Curr Pharm Des 19(18):3210–3214CrossRef

11.

Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM (2006) Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119(3):599–607. https://doi.org/10.1002/ijc.21902 CrossRefPubMed

12.

Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO, Kim JH, Song KS, Rho SM, Yoo HS, Kim YS, Kim JG, Kim NS (2005) Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 11(2 Pt 1):473–482PubMed

13.

Rajkumar T, Sabitha K, Vijayalakshmi N, Shirley S, Bose MV, Gopal G, Selvaluxmy G (2011) Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer 11:80. https://doi.org/10.1186/1471-2407-11-80 CrossRefPubMedPubMedCentral

14.

Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H (2012) Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 5:15–15. https://doi.org/10.1186/1756-8722-5-15 CrossRefPubMedPubMedCentral

15.

Wu W-j, Hu K-s, Wang D-s, Zeng Z-l, Zhang D-s, Chen D-l, Bai L, Xu R-h (2013) CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. J Transl Med 11:142–142. https://doi.org/10.1186/1479-5876-11-142 CrossRefPubMedPubMedCentral

16.

Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M (2012) Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 106(4):423–430. https://doi.org/10.1002/jso.23109 CrossRefPubMed

17.

Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12(2):405–410. https://doi.org/10.1158/1078-0432.ccr-05-0903 CrossRefPubMed

18.

Karra H, Repo H, Ahonen I, Löyttyniemi E, Pitkänen R, Lintunen M, Kuopio T, Söderström M, Kronqvist P (2014) Cdc20 and securin overexpression predict short-term breast cancer survival. Br J Cancer 110(12):2905–2913. https://doi.org/10.1038/bjc.2014.252 CrossRefPubMedPubMedCentral

19.

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352. https://doi.org/10.1038/nature10983 CrossRefPubMedPubMedCentral

20.

Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725–731. https://doi.org/10.1007/s10549-009-0674-9 CrossRef

21.

Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G, Campion L (2012) bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 131(3):765–775. https://doi.org/10.1007/s10549-011-1457-7 CrossRefPubMed

22.

Alfarsi LH, Elansari R, Toss MS, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR (2019) Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. Breast Cancer Res Treat 173(1):93–102. https://doi.org/10.1007/s10549-018-4978-5 CrossRefPubMed

23.

Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350. https://doi.org/10.1002/ijc.21004 CrossRefPubMed

24.

McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716–721PubMed

25.

Clarke R, Tyson JJ, Dixon JM (2015) Endocrine resistance in breast cancer–an overview and update. Molecular and cellular endocrinology 418(Pt 3):220–234. https://doi.org/10.1016/j.mce.2015.09.035 CrossRefPubMedPubMedCentral

26.

Wasch R, Engelbert D (2005) Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24(1):1–10. https://doi.org/10.1038/sj.onc.1208017 CrossRefPubMed

27.

Taniguchi K, Momiyama N, Ueda M, Matsuyama R, Mori R, Fujii Y, Ichikawa Y, Endo I, Togo S, Shimada H (2008) Targeting of CDC20 via small interfering RNA causes enhancement of the cytotoxicity of chemoradiation. Anticancer Res 28(3a):1559–1563PubMed

28.

Li J, Gao JZ, Du JL, Huang ZX, Wei LX (2014) Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol 45(4):1547–1555. https://doi.org/10.3892/ijo.2014.2559 CrossRefPubMed

29.

Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F (2017) Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 75:284–298. https://doi.org/10.1016/j.ejca.2017.01.017 CrossRefPubMed

30.

Alfarsi L, Johnston S, Liu DX, Rakha E, Green A (2018) Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology. https://doi.org/10.1111/his.13523 CrossRefPubMed

31.

Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T, Chetiyawardana S, Dewar JA, Fernando IN, Grieve R, Nicoll J, Rayter Z, Robinson A, Salman A, Yarnold J, Bathers S, Marshall A, Lee M, Group obota C (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31(18_suppl):5–5. https://doi.org/10.1200/jco.2013.31.18_suppl.5 CrossRef

32.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet (London, England) 381(9869):805–816. https://doi.org/10.1016/s0140-6736(12)61963-1 CrossRef

33.

van Hellemond IEG, Geurts SME, Tjan-Heijnen VCG (2018) Current status of extended adjuvant endocrine therapy in early stage breast cancer. Curr Treat Options Oncol 19(5):26–26. https://doi.org/10.1007/s11864-018-0541-1 CrossRefPubMedPubMedCentral

34.

Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52(7):893–901. https://doi.org/10.1369/jhc.3A6195.2004 CrossRefPubMed

35.

Press MF, Hung G, Godolphin W, Slamon DJ (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Can Res 54(10):2771–2777

36.

Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A, Smith RC (2005) Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 29(9):1125–1134CrossRef

37.

Stark AM, Pfannenschmidt S, Tscheslog H, Maass N, Rosel F, Mehdorn HM, Held-Feindt J (2006) Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: a real-time PCR and immunohistochemical evaluation. Neurol Res 28(8):787–793. https://doi.org/10.1179/016164106x110364 CrossRefPubMed

38.

Dickson BC, Mulligan AM, Zhang H, Lockwood G, O’Malley FP, Egan SE, Reedijk M (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20(6):685–693. https://doi.org/10.1038/modpathol.3800785 CrossRefPubMed

39.

Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG (2018) Reporting recommendations for tumor marker prognostic studies (REMARK): an Abridged Explanation and Elaboration. J Natl Cancer Inst 110(8):803–811. https://doi.org/10.1093/jnci/djy088 CrossRefPubMedPubMedCentral

Titel: CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy
verfasst von: Lutfi H. Alfarsi
Rokaya El Ansari
Madeleine L. Craze
Michael S. Toss
Brendah Masisi
Ian O. Ellis
Emad A. Rakha
Andrew R. Green
Publikationsdatum: 30.08.2019
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05420-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis

Prophylactic acupuncture treatment during chemotherapy with breast cancer: a randomized pragmatic trial with a retrospective nested qualitative study

The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors

Acknowledgement of reviewers 2018

Inherited variants in XRCC2 and the risk of breast cancer

Multiplex ddPCR assay for screening copy number variations in BRCA1 gene

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie